REVIVA PHARMACEUTICALS HOLDINGS, INC.
Closed (deSPAC)Health Care · central nervous system drug development
- What it is
- A private company in health care preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Tenzing Acquisition Corp. (TZAC) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
What the company says about itself
Web research — not audited[WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Reviva raised capital through a March 2026 public offering, which delivered net proceeds of about $8.9 million" [https://www.stocktitan.net/sec-filings/RVPH/10-q-reviva-pharmaceuticals-holdings-inc-quarterly-earnings-report-4ac2eba9d6c4.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Management believes existing cash can fund operations into July 2027" [https://www.stocktitan.net/sec-filings/RVPH/10-q-reviva-pharmaceuticals-holdings-inc-quarterly-earnings-report-4ac2eba9d6c4.html]
Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
REVIVA PHARMACEUTICALS HOLDINGS, INC. is merging with Tenzing Acquisition Corp. (TZAC) currently marked Closed (deSPAC).
| Headline equity value | — |
How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is REVIVA PHARMACEUTICALS HOLDINGS, INC. going public?
REVIVA PHARMACEUTICALS HOLDINGS, INC. has an approved merger with the SPAC Tenzing Acquisition Corp. (TZAC). Deal status: Closed (deSPAC).
Does REVIVA PHARMACEUTICALS HOLDINGS, INC. have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.
- Oak Hill Bio — with RACC ($160M) · pre-revenue
- Longevity Biomedical — with FTII ($100M) · pre-revenue
- GNQ Insilico — with IBAC ($500M)
- HCC Healthcare Pte. — with RFAM ($500M)
- OmniAb — with AHPA
- Jasper Therapeutics — with AMHC